- Home
- ACRS vs FF Comparison
ACRS vs FF Comparison
Compare ACRS & FF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- FF
- Stock Information
- Founded
- ACRS 2012
- FF N/A
- Country
- ACRS United States
- FF United States
- Employees
- ACRS N/A
- FF N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- FF Major Chemicals
- Sector
- ACRS Health Care
- FF Industrials
- Exchange
- ACRS Nasdaq
- FF Nasdaq
- Market Cap
- ACRS 165.7M
- FF 176.1M
- IPO Year
- ACRS 2015
- FF N/A
- Fundamental
- Price
- ACRS $1.80
- FF $3.88
- Analyst Decision
- ACRS Strong Buy
- FF
- Analyst Count
- ACRS 9
- FF 0
- Target Price
- ACRS $9.25
- FF N/A
- AVG Volume (30 Days)
- ACRS 1.4M
- FF 283.9K
- Earning Date
- ACRS 08-07-2025
- FF 08-11-2025
- Dividend Yield
- ACRS N/A
- FF 6.47%
- EPS Growth
- ACRS N/A
- FF N/A
- EPS
- ACRS N/A
- FF N/A
- Revenue
- ACRS $16,789,000.00
- FF $165,860,000.00
- Revenue This Year
- ACRS N/A
- FF N/A
- Revenue Next Year
- ACRS $8.11
- FF N/A
- P/E Ratio
- ACRS N/A
- FF N/A
- Revenue Growth
- ACRS N/A
- FF N/A
- 52 Week Low
- ACRS $1.05
- FF $3.58
- 52 Week High
- ACRS $5.17
- FF $6.40
- Technical
- Relative Strength Index (RSI)
- ACRS 62.45
- FF 50.41
- Support Level
- ACRS $1.75
- FF $3.60
- Resistance Level
- ACRS $1.92
- FF $3.79
- Average True Range (ATR)
- ACRS 0.09
- FF 0.14
- MACD
- ACRS 0.01
- FF 0.01
- Stochastic Oscillator
- ACRS 70.00
- FF 81.94
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About FF FutureFuel Corp. Common shares
FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuel segment sells biodiesel and other petroleum products. Its fuels are made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment sells products that are used in the production of agricultural chemicals, which include herbicides, coatings, and cleaning products, such as detergents.